Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28202864 | 0.87 | OPRM1 (0.56) | OPRM1SLC6A4OPRD1OPRK1 | |
| SCHEMBL26637985 | 0.82 | OPRM1 (0.52) | OPRM1SLC6A4OPRD1OPRK1 | |
| SCHEMBL31436663 | 0.82 | OPRM1 (0.54) | OPRM1SLC6A4OPRD1OPRK1 | |
| SCHEMBL26637710 | 0.82 | OPRM1 (0.54) | OPRM1SLC6A4OPRD1OPRK1 | |
| SCHEMBL26638096 | 0.81 | OPRM1 (0.50) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31685910 | 0.81 | OPRM1 (0.50) | OPRM1OPRD1OPRK1 | |
| SCHEMBL26637711 | 0.81 | OPRM1 (0.61) | OPRM1POLBSLC6A4OPRD1OPRK1 | |
| SCHEMBL26637724 | 0.79 | OPRM1 (0.55) | OPRM1POLBSLC6A4OPRD1OPRK1 | |
| SCHEMBL31436682 | 0.77 | SLC6A2 (0.42) | OPRM1SLC6A2SLC6A4SLC6A3OPRD1 | |
| SCHEMBL26637666 | 0.77 | SLC6A2 (0.42) | OPRM1SLC6A2SLC6A4SLC6A3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288556-A1 | Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of CNS disorders | EQUINORM LTD (FI) | 2025-09-18 | — | — | US | claimed |
| CN-119486999-A | Azetidine compounds, pharmaceutical compositions thereof, methods of preparation and their use in the treatment of CNS disorders | 伊科诺姆有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20250288556-A1 | Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of CNS disorders | EQUINORM LTD (FI) | 2025-09-18 | — | — | US | disclosed |
| CN-119486999-A | Azetidine compounds, pharmaceutical compositions thereof, methods of preparation and their use in the treatment of CNS disorders | 伊科诺姆有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023214119-A1 | AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHODS AND THEIR USES IN THE TREATMENT OF CNS DISORDERS | EQUINORM LTD (FI) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023214119-A1 | AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHODS AND THEIR USES IN THE TREATMENT OF CNS DISORDERS | EQUINORM LTD (FI) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288556-A1 | Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of CNS disorders | CYP2C9, DRD2, CYP2C19 | OPRM1 24/4885POLB 4491/4885SLC6A2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.